blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1765391

EP1765391 - BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.01.2014
Database last updated on 03.01.2025
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Qu Biologics Inc.
887 Great Northern Way
Vancouver, BC V5T 4T5 / CA
[N/P]
Former [2011/35]For all designated states
Qu Biologics Inc
887 Great Northern Way
Vancouver, BC V5T 4T5 / CA
Former [2007/13]For all designated states
Gunn, Harold David
1116 Ironwork Passage
Vancouver, BC V6H 3P1 / CA
Inventor(s)01 / Gunn Harold D.
887 Great Northern Way
Vancouver, BC V5T 4T5 / CA
 [2011/35]
Former [2007/13]01 / see applicant
...
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2013/10]Wright, Andrew John
Potter Clarkson LLP The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2007/13]Wright, Andrew John
Eric Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham, NG1 5DD / GB
Application number, filing date05748702.730.05.2005
[2007/13]
WO2005CA00812
Priority number, dateUS20040577206P07.06.2004         Original published format: US 577206 P
[2007/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005120560
Date:22.12.2005
Language:EN
[2005/51]
Type: A1 Application with search report 
No.:EP1765391
Date:28.03.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 22.12.2005 takes the place of the publication of the European patent application.
[2007/13]
Type: B1 Patent specification 
No.:EP1765391
Date:06.03.2013
Language:EN
[2013/10]
Search report(s)International search report - published on:CA22.12.2005
(Supplementary) European search report - dispatched on:EP10.01.2008
ClassificationIPC:A61K39/02, A61P35/00, A61K35/74, A61P37/04
[2007/13]
CPC:
A61K35/744 (EP,US); A61K35/74 (EP,US); A61K35/742 (EP,US);
A61K39/02 (EP,US); A61K39/0258 (EP,US); A61K39/0266 (EP,US);
A61K39/05 (EP,US); A61K39/085 (EP,US); A61K39/092 (EP,US);
A61K39/095 (EP,US); A61K39/102 (EP,US); A61K39/1045 (EP,US);
A61P1/18 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/04 (EP); A61P43/00 (EP); A61K2039/521 (EP,US);
A61K2039/585 (EP,US); A61K2039/70 (EP,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/13]
TitleGerman:BAKTERIELLE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS[2007/13]
English:BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER[2007/13]
French:COMPOSITIONS BACTERIENNES POUR LE TRAITEMENT D'UN CANCER[2007/13]
Entry into regional phase04.01.2007National basic fee paid 
04.01.2007Search fee paid 
04.01.2007Designation fee(s) paid 
04.01.2007Examination fee paid 
Examination procedure03.01.2007Amendment by applicant (claims and/or description)
04.01.2007Examination requested  [2007/13]
02.07.2008Despatch of a communication from the examining division (Time limit: M06)
08.01.2009Reply to a communication from the examining division
16.06.2009Despatch of a communication from the examining division (Time limit: M06)
24.11.2009Reply to a communication from the examining division
23.04.2010Despatch of a communication from the examining division (Time limit: M06)
22.10.2010Reply to a communication from the examining division
07.04.2011Despatch of a communication from the examining division (Time limit: M04)
06.05.2011Reply to a communication from the examining division
25.05.2011Despatch of a communication from the examining division (Time limit: M04)
16.08.2011Reply to a communication from the examining division
16.11.2011Despatch of a communication from the examining division (Time limit: M04)
06.01.2012Reply to a communication from the examining division
09.03.2012Despatch of a communication from the examining division (Time limit: M06)
16.08.2012Reply to a communication from the examining division
21.09.2012Communication of intention to grant the patent
25.01.2013Fee for grant paid
25.01.2013Fee for publishing/printing paid
Divisional application(s)EP10075497.7  / EP2286832
EP14172431.0  / EP2801371
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.07.2008
Opposition(s)09.12.2013No opposition filed within time limit [2014/07]
Fees paidRenewal fee
14.05.2007Renewal fee patent year 03
28.05.2008Renewal fee patent year 04
26.05.2009Renewal fee patent year 05
26.05.2010Renewal fee patent year 06
27.05.2011Renewal fee patent year 07
29.05.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.05.2005
CY06.03.2013
CZ06.03.2013
EE06.03.2013
LT06.03.2013
MC06.03.2013
RO06.03.2013
SI06.03.2013
SK06.03.2013
LU30.05.2013
BG06.06.2013
IS06.07.2013
PT08.07.2013
[2015/34]
Former [2014/03]CY06.03.2013
CZ06.03.2013
EE06.03.2013
LT06.03.2013
MC06.03.2013
RO06.03.2013
SI06.03.2013
SK06.03.2013
BG06.06.2013
IS06.07.2013
PT08.07.2013
Former [2013/52]CY06.03.2013
CZ06.03.2013
EE06.03.2013
LT06.03.2013
RO06.03.2013
SI06.03.2013
SK06.03.2013
BG06.06.2013
IS06.07.2013
PT08.07.2013
Former [2013/49]CZ06.03.2013
EE06.03.2013
LT06.03.2013
RO06.03.2013
SI06.03.2013
SK06.03.2013
BG06.06.2013
IS06.07.2013
PT08.07.2013
Former [2013/48]EE06.03.2013
LT06.03.2013
SI06.03.2013
BG06.06.2013
IS06.07.2013
PT08.07.2013
Former [2013/47]LT06.03.2013
SI06.03.2013
BG06.06.2013
PT08.07.2013
Former [2013/37]LT06.03.2013
SI06.03.2013
BG06.06.2013
Former [2013/34]LT06.03.2013
BG06.06.2013
Former [2013/33]LT06.03.2013
Documents cited:Search[X]WO9526742  (UNIV LONDON [GB], et al) [X] 1-30 * the whole document *;
 [X]WO03049751  (KHAMAR BAKULESH MAFATLAL [IN]) [X] 1-30 * the whole document *;
 [X]EP1415655  (HAYASHI AKIRA [JP], et al) [X] 1-30 * the whole document *;
 [X]  - HROUDA D ET AL, "Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).", BRITISH JOURNAL OF UROLOGY OCT 1998, (199810), vol. 82, no. 4, ISSN 0007-1331, pages 568 - 573, XP009045425 [X] 1-30 * the whole document *
International search[X]WO0156387  (DONNELL MICHAEL A O [US]);
 [Y]WO03049752  (PASTEUR INSTITUT [FR], et al);
 [X]WO03063593  (VION PHARMACEUTICALS INC [US], et al);
 [Y]  - ASSERSOHN L ET AL, "A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.", CLIN ONCOL., (200202), vol. 14, no. 1, pages 23 - 27, XP008092251

DOI:   http://dx.doi.org/10.1053/clon.2001.0030
 [YP]  - O'BRIEN MER ET AL, "SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.", ANN ONCOL., (200406), vol. 15, no. 6, pages 906 - 914, XP008092109

DOI:   http://dx.doi.org/10.1093/annonc/mdh220
 [A]  - SYLVESTER RJ ET AL, "Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.", J UROL., (200211), vol. 168, no. 5, pages 1964 - 1970, XP005539962

DOI:   http://dx.doi.org/10.1016/S0022-5347(05)64273-5
ExaminationUS3928565
 US4329452
    - M.A. BEHR ET AL., "Comparative genomics of BCG vaccines by whole-genome DNA microarray", SCIENCE, (19990528), vol. 284, no. 1520, pages 1520 - 1523
    - WOFGANG LEIBL, "Corynebacterium - Nonmedical", THE PROKARYOTES, (2006), vol. 3, page 796
    - BARBARA A. BROWN-ELLIOT ET AL., "Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy", CLINICAL MICROBIOLOGY REVIEWS, (200604), vol. 19, no. 2, pages 259 - 260
    - "Chapter 29 Enterobacteriaceae", Medical Microbiology, Mosby, Inc., (1998), pages 237 - 239
    - "Chapter 32 Pseudomonas and Related Organisms", Medical Microbiology, Mosby, Inc., (1998), pages 260 - 261
    - "Chapter 40 Mycobacterium", Medical Microbiology, Mosby Inc., (1998), pages 321 - 323
    - CANN S A HOPTION ET AL, "Dr William Coley and tumour regression: A place in history or in the future.", POSTGRADUATE MEDICAL JOURNAL, (200312), vol. 79, no. 938, ISSN 0032-5473, pages 672 - 680
    - CANN S A HOPTION ET AL, "Spontaneous regression: A hidden treasure buried in time", MEDICAL HYPOTHESES, (200202), vol. 58, no. 2, ISSN 0306-9877, pages 115 - 119
    - TANG Z Y ET AL, "PRELIMINARY RESULT OF MIXED BACTERIAL VACCINE AS ADJUVANT TREATMENT OF HEPATOCELLULAR CARCINOMA", MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, STOCKTON PRESS, HANTS, GB, vol. 8, no. 1, doi:10.1007/BF02988567, ISSN 0736-0118, (19910301), pages 23 - 28, (20081116), XP008149065

DOI:   http://dx.doi.org/10.1007/BF02988567
by applicantUS3928565
 US4329452
 WO03063593
 EP1415655
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.